Trials / Recruiting
RecruitingNCT07156149
Fabhalta Capsules Specified Drug-use Survey
Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 0 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Conditions
Timeline
- Start date
- 2025-09-17
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
- First posted
- 2025-09-05
- Last updated
- 2026-04-13
Locations
26 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT07156149. Inclusion in this directory is not an endorsement.